Cantargia publishes interim report for first quarter 2022
Cantargia AB’s (”Cantargia”) interim report for first quarter 2022 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the first quarter · Clinical development of nadunolimab in pancreatic cancer (PDAC) was advanced by including nadunolimab in Pancreatic Cancer Action Network’s (PanCAN) phase II/III clinical trial Precision Promise℠. · The first patient with non-squamous non-small cell lung cancer (NSCLC) was treated in a new arm in CANFOUR, and the first patient with triple-negative breast cancer was treated in the